PHARNEXT (EPA:ALPHA) Pharnext enters the final stretch for the signature of a licensing agreement for its drug candidate in Charcot Marie Tooth disease type 1A, enabling it to capitalize on its assets and put an end to the OCEANE BSA financing line
Transparency directive : regulatory news
20/09/2023 08:30